Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 7082696, 14 pages
https://doi.org/10.1155/2017/7082696
Review Article

mTOR-Dependent Cell Proliferation in the Brain

1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126 Pisa, Italy
2I.R.C.C.S. Neuromed, Via Atinense 18, Pozzilli, 86077 Isernia, Italy

Correspondence should be addressed to Francesco Fornai; ti.ipinu.dem@ianrof.ocsecnarf

Received 17 July 2017; Accepted 22 October 2017; Published 13 November 2017

Academic Editor: Marta M. Alonso

Copyright © 2017 Larisa Ryskalin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Laplante and D. M. Sabatini, “MTOR signaling in growth control and disease,” Cell, vol. 149, no. 2, pp. 274–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Vézina, A. Kudelski, and S. N. Sehgal, “Rapamycin (AY 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle,” The Journal of Antibiotics, vol. 28, no. 10, pp. 721–726, 1975. View at Publisher · View at Google Scholar · View at Scopus
  3. S. N. Sehgal, “Sirolimus: its discovery, biological properties, and mechanism of action,” Transplantation Proceedings, vol. 35, no. 3, pp. 7S–14S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. E. J. Brown, M. W. Albers, K. Ichikawa, C. T. Keith, W. S. Lane, and S. L. Schreiber, “A mammalian protein targeted by G1-arresting rapamycin-receptor complex,” Nature, vol. 369, no. 6483, pp. 756–758, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Liu, Y. Cheng, Q. Liu, J. Bao, and J. Yang, “Autophagic pathways as new targets for cancer drug development,” Acta Pharmacologica Sinica, vol. 31, no. 9, pp. 1154–1164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Zoncu, A. Efeyan, and D. M. Sabatini, “mTOR: from growth signal integration to cancer, diabetes and ageing,” Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Loewith, E. Jacinto, S. Wullschleger et al., “Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control,” Molecular Cell, vol. 10, no. 3, pp. 457–468, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. D. A. Guertin and D. M. Sabatini, “An expanding role for mTOR in cancer,” Trends in Molecular Medicine, vol. 11, no. 8, pp. 353–361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. D. D. Sarbassov, S. M. Ali, and D. M. Sabatini, “Growing roles for the mTOR pathway,” Current Opinion in Cell Biology, vol. 17, no. 6, pp. 596–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Wullschleger, R. Loewith, and M. N. Hall, “TOR signaling in growth and metabolism,” Cell, vol. 124, no. 3, pp. 471–484, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Hara, Y. Maruki, X. Long et al., “Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action,” Cell, vol. 110, no. 2, pp. 177–189, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. D.-H. Kim, D. D. Sarbassov, S. M. Ali et al., “mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery,” Cell, vol. 110, no. 2, pp. 163–175, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes & Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Sancak, C. C. Thoreen, T. R. Peterson et al., “PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase,” Molecular Cell, vol. 25, no. 6, pp. 903–915, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Laplante and D. M. Sabatini, “mTOR signaling at a glance,” Journal of Cell Science, vol. 122, no. 20, pp. 3589–3594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. R. Peterson, M. Laplante, and C. C. Thoreen, “DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival,” Cell, vol. 137, no. 5, pp. 873–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Guertin, D. M. Stevens, C. C. Thoreen et al., “Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1,” Developmental Cell, vol. 11, no. 6, pp. 859–871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. D. Sarbassov, S. M. Ali, D. H. Kim et al., “Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton,” Current Biology, vol. 14, no. 14, pp. 1296–1302, 2004. View at Google Scholar
  19. M. A. Frias, C. C. Thoreen, J. D. Jaffe et al., “mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s,” Current Biology, vol. 16, no. 18, pp. 1865–1870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. L. R. Pearce, X. Huang, J. Boudeau et al., “Identification of protor as a novel Rictor-binding component of mTOR complex-2,” The Biochemical Journal, vol. 405, no. 3, pp. 513–522, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Jacinto, R. Loewith, A. Schmidt et al., “Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive,” Nature Cell Biology, vol. 6, no. 11, pp. 1122–1128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Gulati, M. Karsy, L. Albert, R. Murali, and M. Jhanwar-Uniyal, “Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility,” International Journal of Oncology, vol. 35, no. 4, pp. 731–740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Kaizuka, T. Hara, N. Oshiro et al., “Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly,” The Journal of Biological Chemistry, vol. 285, no. 26, pp. 20109–20116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Haissaguerre, N. Saucisse, and D. Cota, “Influence of mTOR in energy and metabolic homeostasis,” Molecular and Cellular Endocrinology, vol. 397, no. 1-2, pp. 67–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. D. C. Fingar and J. Blenis, “Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression,” Oncogene, vol. 23, no. 18, pp. 3151–3171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. X. M. Ma and J. Blenis, “Molecular mechanisms of mTOR-mediated translational control,” Nature Reviews Molecular Cell Biology, vol. 10, no. 5, pp. 307–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. E. Kim and J. Chen, “Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis,” Diabetes, vol. 53, no. 11, pp. 2748–2756, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Porstmann, C. R. Santos, B. Griffiths et al., “SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth,” Cell Metabolism, vol. 8, no. 3, pp. 224–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. T. Cunningham, J. T. Rodgers, D. H. Arlow, F. Vazquez, V. K. Mootha, and P. Puigserver, “mTOR controls mitochondrial oxidative function through a YY1-PGC-1α transcriptional complex,” Nature, vol. 450, no. 7170, pp. 736–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Chen, Y. Liu, R. Liu et al., “TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species,” The Journal of Experimental Medicine, vol. 205, no. 10, pp. 2397–2408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Eskelinen, “Maturation of autophagic vacuoles in mammalian cells.,” Autophagy, vol. 1, no. 1, pp. 1–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. J. Lum, R. J. DeBerardinis, and C. B. Thompson, “Autophagy in metazoans: cell survival in the land of plenty,” Nature Reviews Molecular Cell Biology, vol. 6, no. 6, pp. 439–448, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Xie and D. J. Klionsky, “Autophagosome formation: core machinery and adaptations,” Nature Cell Biology, vol. 9, no. 10, pp. 1102–1109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. I. G. Ganley, D. H. Lam, J. Wang, X. Ding, S. Chen, and X. Jiang, “ULK1·ATG13·FIP200 complex mediates mTOR signaling and is essential for autophagy,” The Journal of Biological Chemistry, vol. 284, no. 18, pp. 12297–12305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. P. Neufeld, “TOR-dependent control of autophagy: Biting the hand that feeds,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 157–168, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Mariño and C. López-Otín, “Autophagy: molecular mechanisms, physiological functions and relevance in human pathology,” Cellular and Molecular Life Sciences, vol. 61, no. 12, pp. 1439–1454, 2004. View at Publisher · View at Google Scholar
  37. D. Akhavan, T. F. Cloughesy, and P. S. Mischel, “mTOR signaling in glioblastoma: Lessons learned from bench to bedside,” Neuro-Oncology, vol. 12, no. 8, pp. 882–889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. Q.-W. Fan and W. A. Weiss, “Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors,” Methods in Molecular Biology, vol. 821, pp. 349–359, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Choi, J. Chen, S. L. Schreiber, and J. Clardy, “Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP,” Science, vol. 273, no. 5272, pp. 239–242, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. J. L. Crespo and M. N. Hall, “Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae,” Microbiology and Molecular Biology Reviews, vol. 66, no. 4, pp. 579–591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Faivre, G. Kroemer, and E. Raymond, “Current development of mTOR inhibitors as anticancer agents,” Nature Reviews Drug Discovery, vol. 5, no. 8, pp. 671–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Li, S. G. Kim, and J. Blenis, “Rapamycin: one drug, many effects,” Cell Metabolism, vol. 19, no. 3, pp. 373–379, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Zheng and Y. Jiang, “mTOR inhibitors at a glance,” Molecular and Cellular Pharmacology, vol. 7, no. 2, pp. 15–20, 2015. View at Google Scholar
  44. D. D. Sarbassov, S. M. Ali, S. Sengupta et al., “Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB,” Molecular Cell, vol. 22, no. 2, pp. 159–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Hara, K. Yonezawa, Q.-P. Weng, M. T. Kozlowski, C. Belham, and J. Avruch, “Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism,” The Journal of Biological Chemistry, vol. 273, no. 23, pp. 14484–14494, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Long, S. Ortiz-Vega, Y. Lin, and J. Avruch, “Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency,” The Journal of Biological Chemistry, vol. 280, no. 25, pp. 23433–23436, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Takei, N. Inamura, M. Kawamura et al., “Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites,” The Journal of Neuroscience, vol. 24, no. 44, pp. 9760–9769, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Quevedo, M. Salinas, and A. Alcázar, “Regulation of cap-dependent translation by insulin-like growth factor-1 in neuronal cells,” Biochemical and Biophysical Research Communications, vol. 291, no. 3, pp. 560–566, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. B. W. Kim, M. Choi, Y.-S. Kim et al., “Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin,” Cellular Signalling, vol. 20, no. 4, pp. 714–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-J. Yao, J. Sun, Q.-R. Zhao, C.-Y. Wang, and Y.-A. Mei, “Neuregulin-1/ErbB4 signaling regulates Kv4.2-mediated transient outward K+ current through the Akt/mTOR pathway,” American Journal of Physiology-Cell Physiology, vol. 305, no. 2, pp. C197–C206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Huang and B. D. Manning, “The TSC1-TSC2 complex: a molecular switchboard controlling cell growth,” The Biochemical Journal, vol. 412, no. 2, pp. 179–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Nie, A. Di Nardo, J. M. Han et al., “Tsc2-Rheb signaling regulates EphA-mediated axon guidance,” Nature Neuroscience, vol. 13, no. 2, pp. 163–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Jaworski, S. Spangler, D. P. Seeburg, C. C. Hoogenraad, and M. Sheng, “Control of dendritic arborization by the phosphoinositide-3-kinase-Akt-mammalian target of rapamycin pathway,” The Journal of Neuroscience, vol. 25, no. 49, pp. 11300–11312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Jossin and A. M. Goffinet, “Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth,” Molecular and Cellular Biology, vol. 27, no. 20, pp. 7113–7124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Santini, M. Heiman, P. Greengard, E. Valjent, and G. Fisone, “Inhibition of mTOR signaling in parkinson's disease prevents L-DOPA-induced dyskinesia,” Science Signaling, vol. 2, no. 80, article ra36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Meffre, S. Chaumont-Dubel, C. Mannoury la Cour et al., “5-HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia,” EMBO Molecular Medicine, vol. 4, no. 10, pp. 1043–1056, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. M.-J. Salles, D. Hervé, J.-M. Rivet et al., “Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens,” Journal of Neurochemistry, vol. 125, no. 4, pp. 532–544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. E. R. Workman, F. Niere, and K. F. Raab-Graham, “mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling,” Neuropharmacology, vol. 73, pp. 192–203, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Takei and H. Nawa, “mTOR signaling and its roles in normal and abnormal brain development,” Frontiers in Molecular Neuroscience, vol. 7, no. 1, article 28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Huang, B. N. Kang, J. Tian et al., “The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway,” The Journal of Neuroscience, vol. 27, no. 3, pp. 449–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. A. Burket, A. D. Benson, A. H. Tang, and S. I. Deutsch, “NMDA receptor activation regulates sociability by its effect on mTOR signaling activity,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 60, pp. 60–65, 2015. View at Google Scholar
  62. N. Li, B. Lee, R.-J. Liu et al., “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists,” Science, vol. 329, no. 5994, pp. 959–964, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Hashimoto, “Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine,” Expert Review of Neurotherapeutics, vol. 11, no. 1, pp. 33–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. A. Guertin and D. M. Sabatini, “Defining the role of mTOR in cancer,” Cancer Cell, vol. 12, no. 1, pp. 9–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. L.-A. Julien, A. Carriere, J. Moreau, and P. P. Roux, “mTORC1-activated S6K1 phosphorylates rictor on threonine 1135 and regulates mTORC2 signaling,” Molecular and Cellular Biology, vol. 30, no. 4, pp. 908–921, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. R. J. Shaw and L. C. Cantley, “Ras, PI(3)K and mTOR signalling controls tumour cell growth,” Nature, vol. 441, no. 7092, pp. 424–430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Yang, D. G. Rudge, J. D. Koos, B. Vaidialingam, H. J. Yang, and N. P. Pavletich, “mTOR kinase structure, mechanism and regulation,” Nature, vol. 497, no. 7448, pp. 217–223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. S. T. Wong, J. Athos, X. A. Figueroa et al., “Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP,” Neuron, vol. 23, no. 4, pp. 787–798, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. K. M. Huber, J. C. Roder, and M. F. Bear, “Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1,” Journal of Neurophysiology, vol. 86, no. 1, pp. 321–325, 2001. View at Google Scholar · View at Scopus
  70. S. J. Tang, G. Reis, H. Kang, A.-C. Gingras, N. Sonenberg, and E. M. Schuman, “A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 99, no. 1, pp. 467–472, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Cammalleri, R. Lütjens, F. Berton et al., “Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 100, no. 24, pp. 14368–14373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Ehninger, S. Han, C. Shilyansky et al., “Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis,” Nature Medicine, vol. 14, no. 8, pp. 843–848, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Okada, H. Tanaka, K. Temporin et al., “Akt/mammalian target of rapamycin signaling pathway regulates neurite outgrowth in cerebellar granule neurons stimulated by methylcobalamin,” Neuroscience Letters, vol. 495, no. 3, pp. 201–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Urbanska, A. Gozdz, L. J. Swiech, and J. Jaworski, “Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons,” The Journal of Biological Chemistry, vol. 287, no. 36, pp. 30240–30256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Costa-Mattioli and L. M. Monteggia, “mTOR complexes in neurodevelopmental and neuropsychiatric disorders,” Nature Neuroscience, vol. 16, no. 11, pp. 1537–1543, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. N. W. Hartman, T. V. Lin, L. Zhang, G. E. Paquelet, D. M. Feliciano, and A. Bordey, “mTORC1 targets the translational repressor 4E-BP2, but not S6 kinase 1/2, to regulate neural stem cell self-renewal in vivo,” Cell Reports, vol. 5, no. 2, pp. 433–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Ka, G. Condorelli, J. R. Woodgett, and W.-Y. Kim, “mTOR regulates brain morphogenesis by mediating GSK3 signaling,” Development, vol. 141, no. 21, pp. 4076–4086, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Kassai, Y. Sugaya, S. Noda et al., “Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases,” Cell Reports, vol. 7, no. 5, pp. 1626–1639, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Wakita, Y. Izumi, T. Nakai et al., “Staurosporine induces dopaminergic neurite outgrowth through AMP-activated protein kinase/mammalian target of rapamycin signaling pathway,” Neuropharmacology, vol. 77, pp. 39–48, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. L. A. Wyatt, M. T. Filbin, and H. S. Keirstead, “PTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neuronal progenitor cells,” Journal of Comparative Neurology, vol. 522, no. 12, pp. 2741–2755, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Zhang, F. Ji, Y. Liu et al., “Ezh2 regulates adult hippocampal neurogenesis and memory,” The Journal of Neuroscience, vol. 34, no. 15, pp. 5184–5199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Leitmeyer, A. Glutz, V. Radojevic et al., “Inhibition of mTOR by rapamycin results in auditory hair cell damage and decreased spiral ganglion neuron outgrowth and neurite formation in vitro,” BioMed Research International, vol. 2015, Article ID 925890, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Speranza, T. Giuliano, F. Volpicelli et al., “Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics,” Frontiers in Behavioral Neuroscience, vol. 9, article 62, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Koscielny, A. R. Malik, E. Liszewska et al., “Adaptor complex 2 controls dendrite morphology via mTOR-dependent expression of GluA2,” Molecular Neurobiology, 2017. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Sato, J. Sunayama, K.-I. Matsuda et al., “Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR,” Neuroscience Letters, vol. 470, no. 2, pp. 115–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. G. N. Paliouras, L. K. Hamilton, A. Aumont, S. E. Joppé, F. Barnabé-Heider, and K. J. L. Fernandes, “Mammalian target of rapamycin signaling is a key regulator of the transit-amplifying progenitor pool in the adult and aging forebrain,” The Journal of Neuroscience, vol. 32, no. 43, pp. 15012–15026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Cloëtta, V. Thomanetz, C. Baranek et al., “Inactivation of mTORC1 in the developing brain causes microcephaly and affects gliogenesis,” The Journal of Neuroscience, vol. 33, no. 18, pp. 7799–7810, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. V. Thomanetz, N. Angliker, D. Cloëtta et al., “Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology,” The Journal of Cell Biology, vol. 201, no. 2, pp. 293–308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Agrawal, J. Reynolds, S. Chew, D. A. Lamba, and R. E. Hughes, “DEPTOR is a stemness factor that regulates pluripotency of embryonic stem cells,” The Journal of Biological Chemistry, vol. 289, no. 46, pp. 31818–31826, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. P. B. Crino, “Focal brain malformations: a spectrum of disorders along the mTOR cascade,” Novartis Foundation Symposium, vol. 288, pp. 260–281, 2007. View at Google Scholar · View at Scopus
  91. J. H. Lee, M. Huynh, J. L. Silhavy et al., “De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly,” Nature Genetics, vol. 44, no. 8, pp. 941–945, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Sarnat, L. Flores-Sarnat, P. Crino, W. Hader, and L. Bello-Espinosa, “Hemimegalencephaly: Foetal tauopathy with mTOR hyperactivation and neuronal lipidosis,” Folia Neuropathologica, vol. 50, no. 4, pp. 330–345, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. P. B. Crino, “mTOR signaling in epilepsy: insights from malformations of cortical development,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 4, Article ID a022442, 2015. View at Publisher · View at Google Scholar
  94. K. E. Hentges, B. Sirry, A. Gingeras et al., “FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 98, no. 24, pp. 13796–13801, 2001. View at Publisher · View at Google Scholar
  95. Y.-G. Gangloff, M. Mueller, S. G. Dann et al., “Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development,” Molecular and Cellular Biology, vol. 24, no. 21, pp. 9508–9516, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Murakami, T. Ichisaka, M. Maeda et al., “mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells,” Molecular and Cellular Biology, vol. 24, no. 15, pp. 6710–6718, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Y. Lee, “Roles of mTOR signaling in brain development,” Experimental Neurobiology, vol. 24, no. 3, pp. 177–185, 2015. View at Publisher · View at Google Scholar
  98. J. Bockaert and P. Marin, “mTOR in brain physiology and pathologies,” Physiological Reviews, vol. 95, no. 4, pp. 1157–1187, 2015. View at Publisher · View at Google Scholar · View at Scopus
  99. K. Hentges, K. Thompson, and A. Peterson, “The flat-top gene is required for the expansion and regionalization of the telencephalic primordium,” Development, vol. 126, no. 8, pp. 1601–1609, 1999. View at Google Scholar · View at Scopus
  100. H. Kassai, T. Terashima, M. Fukaya et al., “Rac1 in cortical projection neurons is selectively required for midline crossing of commissural axonal formation,” European Journal of Neuroscience, vol. 28, no. 2, pp. 257–267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Shiota, J.-T. Woo, J. Lindner, K. D. Shelton, and M. A. Magnuson, “Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability,” Developmental Cell, vol. 11, no. 4, pp. 583–589, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. Z. Zhang, G. Zhang, X. Xu, W. Su, and B. Yu, “mTOR-rictor is the Ser473 kinase for AKT1 in mouse one-cell stage embryos,” Molecular and Cellular Biochemistry, vol. 361, no. 1-2, pp. 249–257, 2012. View at Publisher · View at Google Scholar
  103. J. Romine, X. Gao, X.-M. Xu, K. F. So, and J. Chen, “The proliferation of amplifying neural progenitor cells is impaired in the aging brain and restored by the mTOR pathway activation,” Neurobiology of Aging, vol. 36, no. 4, pp. 1716–1726, 2015. View at Publisher · View at Google Scholar · View at Scopus
  104. C. A. Lafourcade, T. V. Lin, D. M. Feliciano, L. Zhang, L. S. Hsieh, and A. Bordey, “Rheb activation in subventricular zone progenitors leads to heterotopia, ectopic neuronal differentiation, and rapamycin-sensitive olfactory micronodules and dendrite hypertrophy of newborn neurons,” The Journal of Neuroscience, vol. 33, no. 6, pp. 2419–2431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. F. S. Giorgi, F. Biagioni, P. Lenzi, A. Frati, and F. Fornai, “The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations,” Journal of Neural Transmission, vol. 122, no. 6, pp. 849–862, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. M. H. Grider, D. Park, D. M. Spencer, and H. D. Shine, “Lipid raft-targeted Akt promotes axonal branching and growth cone expansion via mTOR and Rac1, respectively,” Journal of Neuroscience Research, vol. 87, no. 14, pp. 3033–3042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. J. L. García-Rodríguez, L. Barbier-Torres, S. Fernández-Álvarez et al., “SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling,” Hepatology, vol. 59, no. 5, pp. 1972–1983, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Gobert, L. Topolnik, M. Azzi et al., “Forskolin induction of late-LTP and up-regulation of 5 TOP mRNAs translation via mTOR, ERK, and PI3K in hippocampal pyramidal cells,” Journal of Neurochemistry, vol. 106, no. 3, pp. 1160–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. L. Swiech, M. Perycz, A. Malik, and J. Jaworski, “Role of mTOR in physiology and pathology of the nervous system,” Biochimica et Biophysica Acta, vol. 1784, no. 1, pp. 116–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. L. Stoica, P. J. Zhu, W. Huang, H. Zhou, S. C. Kozma, and M. Costa-Mattioli, “Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, no. 9, pp. 3791–3796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Jia, A. R. Aroor, L. A. Martinez-Lemus, and J. R. Sowers, “Overnutrition, mTOR signaling, and cardiovascular diseases,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 307, no. 10, pp. R1198–R1206, 2014. View at Publisher · View at Google Scholar
  112. K. A. Orlova and P. B. Crino, “The tuberous sclerosis complex,” Annals of the New York Academy of Sciences, vol. 1184, no. 1, pp. 87–105, 2010. View at Publisher · View at Google Scholar
  113. D. M. Feliciano, T. Su, J. Lopez, J. C. Platel, and A. Bordey, “Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice,” The Journal of Clinical Investigation, vol. 121, no. 4, pp. 1596–1607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Poduri, G. D. Evrony, X. Cai et al., “Somatic activation of AKT3 causes hemispheric developmental brain malformations,” Neuron, vol. 74, no. 1, pp. 41–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. W. E. Parker, K. A. Orlova, W. H. Parker et al., “Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder,” Science Translational Medicine, vol. 5, no. 182, Article ID 182ra53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. A. S. Prabowo, J. J. Anink, M. Lammens et al., “Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation,” Brain Pathology, vol. 23, no. 1, pp. 45–59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. I. E. Scheffer, S. E. Heron, B. M. Regan et al., “Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations,” Annals of Neurology, vol. 75, no. 5, pp. 782–787, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Muncy, I. J. Butler, and K. M. Koenig, “Rapamycin reduces seizure frequency in tuberous sclerosis complex,” Journal of Child Neurology, vol. 24, no. 4, p. 477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. B. Zhang, S. S. McDaniel, N. R. Rensing, and M. Wong, “Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex,” PLoS ONE, vol. 8, no. 2, Article ID e57445, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. N. Rensing, L. Han, and M. Wong, “Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex,” Epilepsia, vol. 56, no. 7, pp. 1088–1097, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. J. W. Wheless, “Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy,” Epilepsy & Behavior Case Reports, vol. 4, pp. 63–66, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Sato, “mTOR, a potential target to treat autism spectrum disorder,” CNS and Neurological Disorders—Drug Targets, vol. 15, no. 5, pp. 533–543, 2016. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Kilincaslan, B. E. Kok, P. Tekturk, C. Yalcinkaya, C. Ozkara, and Z. Yapici, “Beneficial effects of everolimus on autism and attention-deficit/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex,” Journal of Child and Adolescent Psychopharmacology, vol. 27, no. 4, pp. 383–388, 2017. View at Publisher · View at Google Scholar
  124. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Agnihotri, K. E. Burrell, A. Wolf et al., “Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies,” Archivum Immunologiae et Therapia Experimentalis, vol. 61, no. 1, pp. 25–41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. D. N. Franz, J. Leonard, C. Tudor et al., “Rapamycin causes regression of astrocytomas in tuberous sclerosis complex,” Annals of Neurology, vol. 59, no. 3, pp. 490–498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. M. E. Tyburczy, K. Kotulska, P. Pokarowski et al., “Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications,” The American Journal of Pathology, vol. 176, no. 4, pp. 1878–1890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. K. M. Koenig, I. J. Butler, and H. Northrup, “Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex,” Journal of Child Neurology, vol. 23, no. 10, pp. 1238-1239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. D. A. Krueger, M. M. Care, K. Holland et al., “Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1801–1811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. T. L. Beaumont, D. D. Limbrick, and M. D. Smyth, “Advances in the management of subependymal giant cell astrocytoma,” Child's Nervous System, vol. 28, no. 7, pp. 963–968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. R. Moavero, A. Coniglio, F. Garaci, and P. Curatolo, “Is mTOR inhibition a systemic treatment for tuberous sclerosis?” Italian Journal of Pediatrics, vol. 39, no. 1, article 57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  132. D. N. Franz, E. Belousova, S. Sparagana et al., “Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial,” The Lancet, vol. 381, no. 9861, pp. 125–132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Roth, E. S. Roach, U. Bartels et al., “Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous sclerosis Complex Consensus Conference 2012,” Pediatric Neurology, vol. 49, no. 6, pp. 439–444, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Jentoft, C. Giannini, L. Cen et al., “Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 1, pp. 43–57, 2011. View at Google Scholar
  135. M. Hütt-Cabezas, M. A. Karajannis, D. Zagzag et al., “Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mtor as a therapeutic target,” Neuro-Oncology, vol. 15, no. 12, pp. 1604–1614, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. J. S. Smith, I. Tachibana, S. M. Passe et al., “PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme,” Journal of the National Cancer Institute, vol. 93, no. 16, pp. 1246–1256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  137. X.-Y. Li, L.-Q. Zhang, X.-G. Zhang et al., “Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas,” Journal of Neuro-Oncology, vol. 103, no. 3, pp. 453–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. P. Korkolopoulou, G. Levidou, E. A. El-Habr et al., “Phosphorylated 4E-binding protein 1 (p-4E-BP1): A novel prognostic marker in human astrocytomas,” Histopathology, vol. 61, no. 2, pp. 293–305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Chakravarti, G. Zhai, Y. Suzuki et al., “The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1926–1933, 2004. View at Publisher · View at Google Scholar · View at Scopus
  140. F. Lefranc, V. Facchini, and R. Kiss, “Proautophagic drugs: A novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas,” The Oncologist, vol. 12, no. 12, pp. 1395–1403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. E. M. Galan-Moya, A. Le Guelte, E. L. Fernandes et al., “Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway,” EMBO Reports, vol. 12, no. 5, pp. 470–476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. W. Zhuang, B. Li, L. Long, L. Chen, Q. Huang, and Z. Liang, “Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity,” International Journal of Cancer, vol. 129, no. 11, pp. 2720–2731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Palumbo, P. Tini, M. Toscano et al., “Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells,” Journal of Cellular Physiology, vol. 229, no. 11, pp. 1863–1873, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. M. Catalano, G. D'Alessandro, F. Lepore et al., “Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells,” Molecular Oncology, vol. 9, no. 8, pp. 1612–1625, 2015. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Garros-Regulez, P. Aldaz, O. Arrizabalaga et al., “mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance,” Expert Opinion on Therapeutic Targets, vol. 20, no. 4, pp. 393–405, 2016. View at Publisher · View at Google Scholar · View at Scopus
  146. P. Kleihues and W. K. Cavenee, World Health Organization; Classification of Tumors: Pathology and Genetic: Tumors of Nervous System, IARC Press, Lyon, France, 2000.
  147. M. Nakada, D. Kita, T. Watanabe et al., “Aberrant signaling pathways in glioma,” Cancers, vol. 3, no. 3, pp. 3242–3278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. F. B. Furnari, T. Fenton, R. M. Bachoo et al., “Malignant astrocytic glioma: genetics, biology and paths to treatment,” Genes & Development, vol. 21, no. 21, pp. 2683–2710, 2007. View at Google Scholar
  149. D. S. Ziegler, A. L. Kung, and M. W. Kieran, “Anti-apoptosis mechanisms in malignant gliomas,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 493–500, 2008. View at Publisher · View at Google Scholar · View at Scopus
  150. C. B. Knobbe, A. Merlo, and G. Reifenberger, “Pten signaling in gliomas,” Neuro-Oncology, vol. 4, pp. 196–211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. D. W. Parsons, S. Jones, X. Zhang et al., “An integrated genomic analysis of human glioblastoma multiforme,” Science, vol. 321, no. 5897, pp. 1807–1812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. D. J. Brat, A. A. Castellano-Sanchez, S. B. Hunter et al., “Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population,” Cancer Research, vol. 64, no. 3, pp. 920–927, 2004. View at Publisher · View at Google Scholar · View at Scopus
  153. S. El Hallani, B. Boisselier, F. Peglion et al., “A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry,” Brain, vol. 133, no. 4, pp. 973–982, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. J. M. Rosen and C. T. Jordan, “The increasing complexity of the cancer stem cell paradigm,” Science, vol. 324, no. 5935, pp. 1670–1673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Zhao, Q. Huang, J. Yang et al., “Autophagy impairment inhibits differentiation of glioma stem/progenitor cells,” Brain Research, vol. 1313, pp. 250–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. N. Goffart, J. Kroonen, and B. Rogister, “Glioblastoma-initiating cells: Relationship with neural stem cells and the micro-environment,” Cancers, vol. 5, no. 3, pp. 1049–1071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Venere, H. A. Fine, P. B. Dirks, and J. N. Rich, “Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy,” Glia, vol. 59, no. 8, pp. 1148–1154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. R. Galli, E. Binda, U. Orfanelli et al., “Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,” Cancer Research, vol. 64, no. 19, pp. 7011–7021, 2004. View at Publisher · View at Google Scholar · View at Scopus
  159. S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of human brain tumour initiating cells,” Nature, vol. 432, no. 7015, pp. 396–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. C. Calabrese, H. Poppleton, M. Kocak et al., “A perivascular niche for brain tumor stem cells,” Cancer Cell, vol. 11, no. 1, pp. 69–82, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. O. Basak and V. Taylor, “Stem cells of the adult mammalian brain and their niche,” Cellular and Molecular Life Sciences, vol. 66, no. 6, pp. 1057–1072, 2009. View at Publisher · View at Google Scholar · View at Scopus
  162. L. Cheng, Z. Huang, W. Zhou et al., “Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth,” Cell, vol. 153, no. 1, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  163. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. W. Zhuang, Z. Qin, and Z. Liang, “The role of autophagy in sensitizing malignant glioma cells to radiation therapy,” Acta Biochimica et Biophysica Sinica, vol. 41, no. 5, pp. 341–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. G. Chandrika, K. Natesh, D. Ranade, A. Chugh, and P. Shastry, “Suppression of the invasive potential of glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling,” Scientific Reports, vol. 6, Article ID 22455, 2016. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Jhanwar-Uniyal, J. L. Gillick, J. Neil, M. Tobias, Z. E. Thwing, and R. Murali, “Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: A tale of two complexes,” Advances in Biological Regulation, vol. 57, pp. 64–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  167. J. Sunayama, A. Sato, K.-I. Matsuda et al., “Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells,” Neuro-Oncology, vol. 12, no. 12, pp. 1205–1219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. A. Arcella, F. Biagioni, M. Antonietta Oliva et al., “Rapamycin inhibits the growth of glioblastoma,” Brain Research, vol. 1495, pp. 37–51, 2013. View at Publisher · View at Google Scholar · View at Scopus
  169. D. J. Ma, E. Galanis, S. K. Anderson et al., “A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K,” Neuro-Oncology, vol. 17, no. 9, pp. 1261–1269, 2015. View at Publisher · View at Google Scholar · View at Scopus
  170. A. A. Stepanenko, S. V. Andreieva, K. V. Korets et al., “mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells,” Gene, vol. 579, no. 1, pp. 58–68, 2016. View at Publisher · View at Google Scholar · View at Scopus
  171. M. Ferrucci, F. Biagioni, P. Lenzi et al., “Rapamycin promotes differentiation increasing βIII-tubulin, NeuN, and NeuroD while suppressing nestin expression in glioblastoma cells,” Oncotarget, vol. 8, no. 18, pp. 29574–29599, 2017. View at Publisher · View at Google Scholar
  172. H. Jiang, E. J. White, C. Conrad, C. Gomez-Manzano, and J. Fueyo, “Autophagy pathways in glioblastoma,” in Methods in Enzymology, vol. 453, chapter 13, pp. 273–286, Elsevier, 2009. View at Publisher · View at Google Scholar
  173. H. Takeuchi, Y. Kondo, K. Fujiwara et al., “Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors,” Cancer Research, vol. 65, no. 8, pp. 3336–3346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. Z. Huang, L. Cheng, O. A. Guryanova, Q. Wu, and S. Bao, “Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting,” Protein & Cell, vol. 1, no. 7, pp. 638–655, 2010. View at Publisher · View at Google Scholar · View at Scopus
  175. G. Chen, G. Rajkowska, F. Du, N. Seraji-Bozorgzad, and H. K. Manji, “Enhancement of hippocampal neurogenesis by lithium,” Journal of Neurochemistry, vol. 75, no. 4, pp. 1729–1734, 2000. View at Publisher · View at Google Scholar · View at Scopus
  176. J. S. Kim, M.-Y. Chang, I. T. Yu et al., “Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo,” Journal of Neurochemistry, vol. 89, no. 2, pp. 324–336, 2004. View at Publisher · View at Google Scholar · View at Scopus
  177. F. Fornai, P. Longone, M. Ferrucci et al., “Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium,” Autophagy, vol. 4, no. 4, pp. 527–530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. A. Wada, “Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3β, β-catenin, and neurotrophin cascades,” Journal of Pharmacological Sciences, vol. 110, no. 1, pp. 14–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  179. L. Pasquali, C. L. Busceti, F. Fulceri, A. Paparelli, and F. Fornai, “Intracellular pathways underlying the effects of lithium,” Behavioural Pharmacology, vol. 21, no. 5-6, pp. 473–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  180. C. Rodolfo, S. Di Bartolomeo, and F. Cecconi, “Autophagy in stem and progenitor cells,” Cellular and Molecular Life Sciences, vol. 73, no. 3, pp. 475–496, 2016. View at Publisher · View at Google Scholar · View at Scopus
  181. N. Gaspar, S. Y. Sharp, S. A. Eccles et al., “Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma,” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1219–1233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  182. R. Liu, J. Li, T. Zhang et al., “Itraconazole suppresses the growth of glioblastoma through induction of autophagy: Involvement of abnormal cholesterol trafficking,” Autophagy, vol. 10, no. 7, pp. 1241–1255, 2014. View at Publisher · View at Google Scholar · View at Scopus
  183. L. Ryskalin, F. Limanaqi, F. Biagioni et al., “The emerging role of m-TOR up-regulation in brain Astrocytoma,” Histology and Histopathology, vol. 32, no. 5, pp. 413–431, 2017. View at Google Scholar
  184. P. Lenzi, G. Lazzeri, F. Biagioni et al., “The autophagoproteasome a novel cell clearing organelle in baseline and stimulated conditions,” Frontiers in Neuroanatomy, vol. 10, article 78, 2016. View at Publisher · View at Google Scholar · View at Scopus
  185. V. Cohen-Kaplan, A. Ciechanover, and I. Livneh, “p62 at the crossroad of the ubiquitin-proteasome system and autophagy,” Oncotarget, vol. 7, no. 51, pp. 83833-83834, 2016. View at Publisher · View at Google Scholar · View at Scopus
  186. A. W. Thomson, H. R. Turnquist, and G. Raimondi, “Immunoregulatory functions of mTOR inhibition,” Nature Reviews Immunology, vol. 9, no. 5, pp. 324–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  187. T. F. Cloughesy, K. Yoshimoto, P. Nghiemphu et al., “Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma,” PLoS Medicine, vol. 5, no. 1, article e8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  188. P. C. De Witt Hamer, “Small molecule kinase inhibitors in glioblastoma: A systematic review of clinical studies,” Neuro-Oncology, vol. 12, no. 3, pp. 304–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. A. Efeyan and D. M. Sabatini, “mTOR and cancer: many loops in one pathway,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 169–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  190. S.-H. Wu, J.-F. Bi, T. Cloughesy, W. K. Cavenee, and P. S. Mischel, “Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance,” Cancer Biology & Medicine, vol. 11, no. 4, pp. 255–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  191. M. Jhanwar-Uniyal, M. Labagnara, M. Friedman, A. Kwasnicki, and R. Murali, “Glioblastoma: Molecular pathways, stem cells and therapeutic targets,” Cancers, vol. 7, no. 2, pp. 538–555, 2015. View at Publisher · View at Google Scholar · View at Scopus
  192. K. Masui, W. K. Cavenee, and P. S. Mischel, “mTORC2 and metabolic reprogramming in GBM: at the interface of genetics and environment,” Brain Pathology, vol. 25, no. 6, pp. 755–759, 2015. View at Publisher · View at Google Scholar · View at Scopus
  193. A. Sami and M. Karsy, “Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding,” Tumor Biology, vol. 34, no. 4, pp. 1991–2002, 2013. View at Publisher · View at Google Scholar · View at Scopus
  194. H. A. Luchman, O. D. M. Stechishin, S. A. Nguyen, X. Q. Lun, J. G. Cairncross, and S. Weiss, “Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival,” Clinical Cancer Research, vol. 20, no. 22, pp. 5756–5767, 2014. View at Publisher · View at Google Scholar · View at Scopus
  195. M. G. Chheda, P. Y. Wen, F. H. Hochberg et al., “Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study,” Journal of Neuro-Oncology, vol. 121, no. 3, pp. 627–634, 2015. View at Publisher · View at Google Scholar · View at Scopus
  196. J. Ma, F. Meng, S. Li et al., “Autophagy induction by endothelial-monocyte activating polypeptide II contributes to the inhibition of malignant biological behaviors by the combination of EMAP II with rapamycin in human glioblastoma,” Frontiers in Molecular Neuroscience, vol. 8, article 74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  197. P. Y. Wen, A. Omuro, M. S. Ahluwalia et al., “Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma,” Neuro-Oncology, vol. 17, no. 9, pp. 1275–1283, 2015. View at Publisher · View at Google Scholar · View at Scopus
  198. X. Li, C. Wu, N. Chen et al., “PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma,” Oncotarget , vol. 7, no. 22, pp. 33440–33450, 2016. View at Publisher · View at Google Scholar · View at Scopus
  199. D. Pachow, W. Wick, D. H. Gutmann, and C. Mawrin, “The mTOR signaling pathway as a treatment target for intracranial neoplasms,” Neuro-Oncology, vol. 17, no. 2, pp. 189–199, 2015. View at Publisher · View at Google Scholar · View at Scopus